Cargando…

In silico drug screening by using genome-wide association study data repurposed dabrafenib, an anti-melanoma drug, for Parkinson’s disease

Parkinson’s disease (PD) is a neurodegenerative disorder characterized by dopaminergic neuron loss. At present, there are no drugs that stop the progression of PD. As with other multifactorial genetic disorders, genome-wide association studies (GWASs) found multiple risk loci for PD, although their...

Descripción completa

Detalles Bibliográficos
Autores principales:	Uenaka, Takeshi, Satake, Wataru, Cha, Pei-Chieng, Hayakawa, Hideki, Baba, Kousuke, Jiang, Shiying, Kobayashi, Kazuhiro, Kanagawa, Motoi, Okada, Yukinori, Mochizuki, Hideki, Toda, Tatsushi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2018
Materias:	Association Studies Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6216208/ https://www.ncbi.nlm.nih.gov/pubmed/30137437 http://dx.doi.org/10.1093/hmg/ddy279

Ejemplares similares

Genome-wide association study identifies zonisamide responsive gene in Parkinson’s disease patients
por: Cha, Pei-Chieng, et al.
Publicado: (2020)

Comparative whole transcriptome analysis of Parkinson’s disease focusing on the efficacy of zonisamide
por: Naito, Tatsuhiko, et al.
Publicado: (2022)

Muscular Dystrophy with Ribitol-Phosphate Deficiency: A Novel Post-Translational Mechanism in Dystroglycanopathy
por: Kanagawa, Motoi, et al.
Publicado: (2017)

CDP-ribitol prodrug treatment ameliorates ISPD-deficient muscular dystrophy mouse model
por: Tokuoka, Hideki, et al.
Publicado: (2022)

Fukutin is prerequisite to ameliorate muscular dystrophic phenotype by myofiber-selective LARGE expression
por: Ohtsuka, Yoshihisa, et al.
Publicado: (2015)

Elimination of fukutin reveals cellular and molecular pathomechanisms in muscular dystrophy-associated heart failure
por: Ujihara, Yoshihiro, et al.
Publicado: (2019)

Treatment of a case of severe insulin resistance as a result of a PIK3R1 mutation with a sodium–glucose cotransporter 2 inhibitor
por: Hamaguchi, Tetsushi, et al.
Publicado: (2018)

Progressive Axonal Degeneration of Nigrostriatal Dopaminergic Neurons in Calcium-Independent Phospholipase A(2)β Knockout Mice
por: Beck, Goichi, et al.
Publicado: (2016)

Trans‐Ethnic Fine‐Mapping of the Major Histocompatibility Complex Region Linked to Parkinson's Disease
por: Naito, Tatsuhiko, et al.
Publicado: (2021)

Contribution of Dysferlin Deficiency to Skeletal Muscle Pathology in Asymptomatic and Severe Dystroglycanopathy Models: Generation of a New Model for Fukuyama Congenital Muscular Dystrophy
por: Kanagawa, Motoi, et al.
Publicado: (2014)

Repurposed and investigational disease-modifying drugs in osteoarthritis (DMOADs)
por: Oo, Win Min, et al.
Publicado: (2022)

Temporal requirement of dystroglycan glycosylation during brain development and rescue of severe cortical dysplasia via gene delivery in the fetal stage
por: Sudo, Atsushi, et al.
Publicado: (2018)

Galectin 3–binding protein suppresses amyloid-β production by modulating β-cleavage of amyloid precursor protein
por: Seki, Tsuneyoshi, et al.
Publicado: (2020)

A de novo mutation of the MYH7 gene in a large Chinese family with autosomal dominant myopathy
por: Oda, Tetsuya, et al.
Publicado: (2015)

Deficiency of Calcium-Independent Phospholipase A2 Beta Induces Brain Iron Accumulation through Upregulation of Divalent Metal Transporter 1
por: Beck, Goichi, et al.
Publicado: (2015)

Potential repurposing of oncology drugs for the treatment of Alzheimer's disease
por: Araki, Wataru
Publicado: (2013)

Japanese WDR45 de novo mutation diagnosed by exome analysis: A case report
por: Endo, Hironobu, et al.
Publicado: (2017)

E46K mutant α-synuclein is more degradation resistant and exhibits greater toxic effects than wild-type α-synuclein in Drosophila models of Parkinson's disease
por: Sakai, Ryusuke, et al.
Publicado: (2019)

Drug repurposing for the treatment of COVID-19
por: Kato, Yuri, et al.
Publicado: (2022)

Editorial: Drug Repurposing
por: Pantziarka, Pan, et al.
Publicado: (2019)

Antifungal Drug Repurposing
por: Kim, Jong H., et al.
Publicado: (2020)

Drug repurposing in cardiology
por: van Driel, B. O., et al.
Publicado: (2020)

Repurposing of antiviral drugs for COVID-19 and impact of repurposed drugs on the nervous system
por: Punekar, Madhura, et al.
Publicado: (2022)

The Anti-Cancer Drug Dabrafenib Is a Potent Activator of the Human Pregnane X Receptor
por: Creusot, Nicolas, et al.
Publicado: (2020)

Characterization of dystroglycan binding in adhesion of human induced pluripotent stem cells to laminin-511 E8 fragment
por: Sugawara, Yumika, et al.
Publicado: (2019)

Crystal structures of fukutin-related protein (FKRP), a ribitol-phosphate transferase related to muscular dystrophy
por: Kuwabara, Naoyuki, et al.
Publicado: (2020)

Drug Repurposing for Schistosomiasis: Combinations of Drugs or Biomolecules
por: Gouveia, Maria João, et al.
Publicado: (2018)

Repurposing of approved cardiovascular drugs
por: Ishida, Junichi, et al.
Publicado: (2016)

Drug repurposing with network reinforcement
por: Nam, Yonghyun, et al.
Publicado: (2019)

Repurposed Drugs in Gastric Cancer
por: Araújo, Diana, et al.
Publicado: (2022)

Amido-bridged nucleic acid (AmNA)-modified antisense oligonucleotides targeting α-synuclein as a novel therapy for Parkinson’s disease
por: Uehara, Takuya, et al.
Publicado: (2019)

On the Integration of In Silico Drug Design Methods for Drug Repurposing
por: March-Vila, Eric, et al.
Publicado: (2017)

Drug Repurposing: An Effective Tool in Modern Drug Discovery
por: Kulkarni, V. S., et al.
Publicado: (2023)

Repurposable Drugs for Immunotherapy and Strategies to Find Candidate Drugs
por: Sakai, Norihiro, et al.
Publicado: (2023)

Inhibition of repulsive guidance molecule-a protects dopaminergic neurons in a mouse model of Parkinson’s disease
por: Oda, Wakana, et al.
Publicado: (2021)

Successful use of dabrafenib after the occurrence of drug rash with eosinophilia and systemic symptoms (DRESS) induced by vemurafenib
por: Pinard, Camille, et al.
Publicado: (2017)

The anti-cancer drug dabrafenib is not cardiotoxic and inhibits cardiac remodelling and fibrosis in a murine model of hypertension
por: Meijles, Daniel N., et al.
Publicado: (2021)

Associations
Publicado: (1860)

Safety of Memantine in Combination with Potentially Interactive Drugs in the Real World: A Pharmacovigilance Study Using the Japanese Adverse Drug Event Report (JADER) Database
por: Sato, Kenichiro, et al.
Publicado: (2021)

GREP: genome for REPositioning drugs
por: Sakaue, Saori, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_tilcr3ao1kj6muvlmdp7uhmduh